What is the share price of IPCA Laboratories Ltd (IPCALAB) today?
The share price of IPCALAB as on 11th July 2025 is ₹1449.60. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on IPCA Laboratories Ltd (IPCALAB) share?
The past returns of IPCA Laboratories Ltd (IPCALAB) share are- Past 1 week: 1.80%
- Past 1 month: 4.61%
- Past 3 months: 8.91%
- Past 6 months: -8.23%
- Past 1 year: 18.45%
- Past 3 years: 47.04%
- Past 5 years: 76.46%
What are the peers or stocks similar to IPCA Laboratories Ltd (IPCALAB)?
The peers or stocks similar to IPCA Laboratories Ltd (IPCALAB) include:What is the market cap of IPCA Laboratories Ltd (IPCALAB) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of IPCA Laboratories Ltd (IPCALAB) is ₹36776.96 Cr as of 11th July 2025.What is the 52 week high and low of IPCA Laboratories Ltd (IPCALAB) share?
The 52-week high of IPCA Laboratories Ltd (IPCALAB) is ₹1755.90 and the 52-week low is ₹1168.20.What is the PE and PB ratio of IPCA Laboratories Ltd (IPCALAB) stock?
The P/E (price-to-earnings) ratio of IPCA Laboratories Ltd (IPCALAB) is 56.51. The P/B (price-to-book) ratio is 5.34.Which sector does IPCA Laboratories Ltd (IPCALAB) belong to?
IPCA Laboratories Ltd (IPCALAB) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy IPCA Laboratories Ltd (IPCALAB) shares?
You can directly buy IPCA Laboratories Ltd (IPCALAB) shares on Tickertape. Simply sign up, connect your demat account and place your order.
IPCA Laboratories Ltd
IPCALAB Share Price
1,449.600.36% (+5.20)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
IPCALAB Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
IPCALAB Performance & Key Metrics
IPCALAB Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 49.85 | 5.34 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.72 | 6.42 | 0.79% |
69%
Analysts have suggested that investors can buy this stock
from 16 analysts
Price Upside
Earnings Growth
Rev. Growth
IPCALAB Company Profile
Ipca Laboratories Limited is engaged in pharmaceuticals business. The Company is a manufacturer and supplier of over 10 active pharmaceutical ingredients (APIs).
SUNPHARMA
PE Ratio
36.71
36.71
1Y Return
5.71%
5.71%
Buy Reco %
87.10
87.10
CIPLA
PE Ratio
22.75
22.75
1Y Return
1.39%
1.39%
Buy Reco %
73.33
73.33
TORNTPHARM
PE Ratio
58.69
58.69
1Y Return
12.03%
12.03%
Buy Reco %
70.83
70.83
MANKIND
PE Ratio
53.44
53.44
1Y Return
21.78%
21.78%
Buy Reco %
81.25
81.25
DRREDDY
PE Ratio
18.46
18.46
1Y Return
4.87%
4.87%
Buy Reco %
50.00
50.00
IPCALAB Sentiment Analysis
IPCALAB Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
IPCALAB Stock Summary · June 2025
Ipca Laboratories demonstrated robust growth in Q4 FY25, achieving a 12% increase in domestic business and outperforming market expectations with a 13.2% growth rate, particularly in the acute segment. However, challenges persist in the chronic segment, where market share remains below competitors. The company is strategically focusing on enhancing operational efficiencies and expanding its product pipeline, with plans to file 67 new products for the U.S. market. Despite facing significant declines in the generic business, particularly in South Africa, management remains cautiously optimistic about future growth, projecting an overall revenue increase of 8% to 10% driven by improved EBITDA margins and a strong emphasis on the U.S. market potential. The integration of Unichem is expected to yield synergies that will further bolster revenue and margin improvements in the coming years.
IPCALAB Stock Growth Drivers
IPCALAB Stock Growth Drivers
8Strong Domestic Business Growth
Ipca Laboratories has reported significant growth in its domestic business, achieving approximately 12% growth in
Market Share Expansion
The company has successfully increased its market share in the 30 metro cities, rising from
IPCALAB Stock Challenges
IPCALAB Stock Challenges
6Export Business Challenges
The export formulation business has faced significant challenges, particularly in the South African market, where
U.S. Market Performance
The U.S. business has not significantly contributed to the overall generic business, with minimal revenue
IPCALAB Forecast
IPCALAB Forecasts
Price
Revenue
Earnings
IPCALAB Share Price Forecast
IPCALAB Share Price Forecast
2025
Current
₹1,449.60
Baseline
Forecast for Jul 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹1,449.60
Baseline
Forecast for Jul 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
IPCALAB Company Revenue Forecast
IPCALAB Company Revenue Forecast
2025
Current
₹6.75
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2025
Current
₹6.75
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
IPCALAB Stock EPS (Earnings Per Share) Forecast
IPCALAB Stock EPS (Earnings Per Share) Forecast
2025
Current
₹25.65
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹25.65
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
IPCALAB
IPCALAB
Income
Balance Sheet
Cash Flow
Annual Normal View
IPCALAB Income Statement
IPCALAB Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 3,122.86 | 3,232.94 | 3,660.25 | 4,402.51 | 5,201.40 | 5,491.22 | 5,925.81 | 6,277.75 | 6,749.21 | 9,032.39 | ||||||||||
Raw Materials | 1,109.15 | 1,091.50 | 1,265.89 | 1,635.75 | 1,753.21 | 1,911.88 | 1,964.94 | 2,033.57 | 1,764.88 | 7,418.50 | ||||||||||
| Power & Fuel Cost | 148.93 | 159.89 | 175.25 | 196.82 | 201.48 | 237.44 | 277.21 | 253.33 | 235.60 | |||||||||||
| Employee Cost | 674.93 | 712.78 | 752.24 | 870.79 | 948.84 | 1,102.14 | 1,193.39 | 1,336.19 | 1,479.34 | |||||||||||
| Selling & Administrative Expenses | 590.38 | 592.45 | 511.56 | 523.99 | 551.23 | 612.89 | 812.67 | 846.95 | 953.42 | |||||||||||
| Operating & Other expenses | 144.28 | 191.70 | 204.95 | 192.66 | 167.83 | 332.70 | 652.14 | 616.49 | 999.17 | |||||||||||
EBITDA | 455.19 | 484.62 | 750.36 | 982.50 | 1,578.81 | 1,294.17 | 1,025.46 | 1,191.22 | 1,316.80 | 1,613.89 | ||||||||||
| Depreciation/Amortization | 171.00 | 174.36 | 171.88 | 178.69 | 187.72 | 209.65 | 228.63 | 246.48 | 251.97 | 397.82 | ||||||||||
| PBIT | 284.19 | 310.26 | 578.48 | 803.81 | 1,391.09 | 1,084.52 | 796.83 | 944.74 | 1,064.83 | 1,216.07 | ||||||||||
| Interest & Other Items | 25.99 | 27.46 | 21.09 | 18.84 | 11.13 | 10.41 | 46.34 | 122.58 | 65.06 | 84.93 | ||||||||||
| PBT | 258.20 | 282.80 | 557.39 | 784.97 | 1,379.96 | 1,074.11 | 750.49 | 822.16 | 999.77 | 1,131.14 | ||||||||||
| Taxes & Other Items | 69.91 | 49.69 | 102.48 | 132.51 | 239.19 | 213.74 | 244.79 | 291.75 | 349.01 | 393.46 | ||||||||||
| Net Income | 188.29 | 233.11 | 454.91 | 652.46 | 1,140.77 | 860.37 | 505.70 | 530.41 | 650.76 | 737.68 | ||||||||||
| EPS | 7.46 | 12.31 | 36.03 | 51.64 | 60.03 | 33.91 | 19.93 | 20.91 | 25.65 | 29.08 | ||||||||||
| DPS | 0.50 | 1.00 | 3.00 | 5.00 | 4.00 | 4.00 | 4.00 | 4.00 | — | 4.00 | ||||||||||
| Payout ratio | 0.07 | 0.08 | 0.08 | 0.10 | 0.07 | 0.12 | 0.20 | 0.19 | 0.00 | 0.14 |
IPCALAB Company Updates
FY 2023FY 2023
IPCALAB Stock Peers
IPCALAB Past Performance & Peer Comparison
IPCALAB Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| IPCA Laboratories Ltd | 56.51 | 5.34 | — |
| Sun Pharmaceutical Industries Ltd | 36.71 | 5.53 | 0.96% |
| Cipla Ltd | 22.75 | 3.83 | 1.08% |
| Torrent Pharmaceuticals Ltd | 58.69 | 14.78 | 0.18% |
IPCALAB Stock Price Comparison
Compare IPCALAB with any stock or ETFCompare IPCALAB with any stock or ETF
IPCALAB
IPCALAB Holdings
IPCALAB Shareholdings
IPCALAB Promoter Holdings Trend
IPCALAB Promoter Holdings Trend
Decreased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has decreased by 1.58%
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
IPCALAB Institutional Holdings Trend
IPCALAB Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
IPCALAB Shareholding Pattern
IPCALAB Shareholding Pattern
IPCALAB Shareholding History
IPCALAB Shareholding History
Foreign Institutions
Mutual Funds Invested in IPCALAB
Mutual Funds Invested in IPCALAB
No mutual funds holding trends are available
Top 5 Mutual Funds holding IPCA Laboratories Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.2171% | Percentage of the fund’s portfolio invested in the stock 4.47% | Change in the portfolio weight of the stock over the last 3 months 1.21% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 7/35 (+6) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0724% | Percentage of the fund’s portfolio invested in the stock 1.11% | Change in the portfolio weight of the stock over the last 3 months -0.35% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 51/69 (-6) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0480% | Percentage of the fund’s portfolio invested in the stock 0.60% | Change in the portfolio weight of the stock over the last 3 months -0.16% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 82/109 (-4) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing IPCALAB stock
smallcases containing IPCALAB stock
Looks like this stock is not in any smallcase yet.
IPCALAB Events
IPCALAB Events
IPCALAB Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
IPCALAB Dividend Trend
No dividend trend available
IPCALAB Upcoming Dividends
IPCALAB Upcoming Dividends
Cash Dividend
Ex DateEx DateAug 5, 2025
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Aug 5, 2025
IPCALAB Past Dividends
IPCALAB Past Dividends
Cash Dividend
Ex DateEx DateNov 27, 2024
Interim
Interim | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Nov 27, 2024
Cash Dividend
Ex DateEx DateAug 6, 2024
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Aug 6, 2024
Cash Dividend
Ex DateEx DateNov 22, 2023
Interim
Interim | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Nov 22, 2023
Cash Dividend
Ex DateEx DateNov 22, 2022
Interim
Interim | Div/Share: ₹4.00
Dividend/Share
₹4.00
Ex DateEx Date
Nov 22, 2022
Cash Dividend
Ex DateEx DateNov 22, 2021
Interim
Interim | Div/Share: ₹8.00
Dividend/Share
₹8.00
Ex DateEx Date
Nov 22, 2021
IPCALAB Stock News & Opinions
IPCALAB Stock News & Opinions
Articles & Videos
Corporate
Ipca Laboratories to hold AGM
Ipca Laboratories announced that the 75th Annual General Meeting(AGM) of the company will be held on 11 August 2025.Powered by Capital Market - Live
1 day agoCapital Market - Live
Corporate
Ipca Laboratories fixes record date for final dividend
Ipca Laboratories has fixed 05 August 2025 as record date for payment of final dividend. Powered by Capital Market - Live
1 day agoCapital Market - Live
Spotlight
Ipca Laboratories Ltd spurts 0.19%, up for five straight sessions
Ipca Laboratories Ltd rose for a fifth straight session today. The stock is quoting at Rs 1460.6, up 0.19% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.03% on the day, quoting at 25468.45. The Sensex is at 83519.94, up 0.09%. Ipca Laboratories Ltd has added around 6.67% in last one month. Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has added around 1.19% in last one month and is currently quoting at 22365.05, down 1.25% on the day. The volume in the stock stood at 71760 shares today, compared to the daily average of 2.54 lakh shares in last one month.The PE of the stock is 44.32 based on TTM earnings ending March 25.Powered by Capital Market - Live
4 days agoCapital Market - Live
Spotlight
Ipca Laboratories Ltd soars 1.25%, Gains for third straight session
Ipca Laboratories Ltd is up for a third straight session in a row. The stock is quoting at Rs 1406.8, up 1.25% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.28% on the day, quoting at 25069.95. The Sensex is at 82276.06, down 0.29%. Ipca Laboratories Ltd has added around 0.19% in last one month. Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has added around 4.05% in last one month and is currently quoting at 22057.15, up 0.76% on the day. The volume in the stock stood at 1.55 lakh shares today, compared to the daily average of 2.94 lakh shares in last one month.The PE of the stock is 42.27 based on TTM earnings ending March 25.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Ipca Laboratories consolidated net profit rises 13.81% in the March 2025 quarter
Net profit of Ipca Laboratories rose 13.81% to Rs 67.82 crore in the quarter ended March 2025 as against Rs 59.59 crore during the previous quarter ended March 2024. Sales rose 10.51% to Rs 2246.69 crore in the quarter ended March 2025 as against Rs 2033.03 crore during the previous quarter ended March 2024. For the full year,net profit rose 34.77% to Rs 737.68 crore in the year ended March 2025 as against Rs 547.35 crore during the previous year ended March 2024. Sales rose 16.02% to Rs 8939.59 crore in the year ended March 2025 as against Rs 7705.04 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales2246.692033.03 11 8939.597705.04 16 OPM %19.0915.83 -19.3117.15 - PBDT433.17311.45 39 1734.011307.66 33 PBT333.05213.32 56 1336.19950.42 41 NP67.8259.59 14 737.68547.35 35 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Board of Ipca Laboratories recommends final dividend
Ipca Laboratories announced that the Board of Directors of the Company at its meeting held on 29 May 2025, inter alia, have recommended the final dividend of Rs 2 per equity Share (i.e. 200%) , subject to the approval of the shareholders.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Ipca Laboratories to announce Quarterly Result
Ipca Laboratories will hold a meeting of the Board of Directors of the Company on 29 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Ipca Laboratories now holds 100% stake in Unichem Laboratories, Ireland
Ipca Laboratories announced that 100% of the paid-up equity share capital of Unichem Laboratories, Ireland is transferred to Ipca Laboratories and, therefore, Unichem Laboratories, Ireland has now become a wholly owned subsidiary of the Company. Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Ipca Laboratories appoints President ' Human Resources
Ipca Laboratories has appointed Saidutta Nanda as President ' Human Resources of the company with effect from 3 March 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Spotlight
Ipca Laboratories Ltd down for fifth straight session
Ipca Laboratories Ltd is down for a fifth straight session today. The stock is quoting at Rs 1356.5, down 0.89% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 1.84% on the day, quoting at 22131.1. The Sensex is at 73233.39, down 1.85%.Ipca Laboratories Ltd has lost around 6.01% in last one month.Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has eased around 6.27% in last one month and is currently quoting at 20201.25, down 1.81% on the day. The volume in the stock stood at 1.28 lakh shares today, compared to the daily average of 4.91 lakh shares in last one month.The PE of the stock is 41.97 based on TTM earnings ending December 24.Powered by Capital Market - Live
4 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 8.92%, vs industry avg of 10%
Over the last 5 years, market share decreased from 1.76% to 1.63%
Over the last 5 years, net income has grown at a yearly rate of -0.05%, vs industry avg of 19.96%